Esperion Therapeutics (ESPR) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

ESPR Stock Forecast


Esperion Therapeutics stock forecast is as follows: an average price target of $16.00 (represents a 700.00% upside from ESPR’s last price of $2.00) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.

ESPR Price Target


The average price target for Esperion Therapeutics (ESPR) is $16.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $12.00. This represents a potential 700.00% upside from ESPR's last price of $2.00.

ESPR Analyst Ratings


Buy

According to 8 Wall Street analysts, Esperion Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ESPR stock is 0 'Strong Buy' (0.00%), 6 'Buy' (75.00%), 2 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Esperion Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 04, 2022Serge BelangerNeedham$12.00$6.5383.77%500.00%
May 04, 2021Derek ArchilaWells Fargo$20.00$25.59-21.84%900.00%
Row per page
Go to

The latest Esperion Therapeutics stock forecast, released on May 04, 2022 by Serge Belanger from Needham, set a price target of $12.00, which represents a 83.77% increase from the stock price at the time of the forecast ($6.53), and a 500.00% increase from ESPR last price ($2.00).

Esperion Therapeutics Price Target by Period


1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$2.00$2.00$2.00
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Esperion Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Esperion Therapeutics's last price of $2.00. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 03, 2024H.C. WainwrightBuyBuyHold
Jul 01, 2024H.C. WainwrightBuyBuyHold
Jun 20, 2024Bank of America SecuritiesBuyUnderperformDowngrade
May 22, 2024H.C. WainwrightBuyBuyHold
Jun 15, 2023Barclays-OverweightInitialise
Jun 15, 2023Guggenheim-BuyInitialise
Jun 15, 2023Cowen & Co.-BuyUpgrade
Jun 15, 2023Bank of America Securities-BuyUpgrade
Mar 16, 2023NeedhamBuyBuyHold
Mar 07, 2023Credit Suisse-NeutralUpgrade
Row per page
Go to

Esperion Therapeutics's last stock rating was published by H.C. Wainwright on Oct 03, 2024. The company gave ESPR a "Buy" rating, the same as its previous rate.

Esperion Therapeutics Financial Forecast


Esperion Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$33.97M$25.79M$24.33M$18.82M$18.98M$18.84M$18.84M$15.40M$14.41M$40.66M$7.98M$9.64M$3.83M$212.24M$1.84M$982.00K$981.00K
Avg Forecast$99.00M$90.70M$83.70M$77.90M$190.80M$92.10M$73.80M$65.10M$61.12M$51.31M$47.49M$83.93M$28.65M$29.59M$24.64M$21.98M$20.61M$19.68M$18.62M$15.41M$14.48M$11.89M$42.18M$19.93M$12.52M$4.01M$147.97M$471.36K$891.80K$900.00K
High Forecast$99.00M$90.70M$83.70M$77.90M$190.80M$92.10M$73.80M$65.10M$61.12M$60.96M$47.49M$83.93M$32.62M$29.59M$24.64M$21.98M$20.61M$19.68M$18.62M$15.41M$14.48M$11.89M$42.18M$19.93M$12.52M$4.01M$147.97M$471.36K$891.80K$900.00K
Low Forecast$99.00M$90.70M$83.70M$77.90M$190.80M$92.10M$73.80M$65.10M$61.12M$45.25M$47.49M$83.93M$22.09M$29.59M$24.64M$21.98M$20.61M$19.68M$18.62M$15.41M$14.48M$11.89M$42.18M$19.93M$12.52M$4.01M$147.97M$471.36K$891.80K$900.00K
# Analysts444433334543633344443333333344
Surprise %-------------1.15%1.05%1.11%0.91%0.96%1.01%1.22%1.06%1.21%0.96%0.40%0.77%0.96%1.43%3.90%1.10%1.09%

Esperion Therapeutics's average Quarter revenue forecast for Dec 23 based on 6 analysts is $28.65M, with a low forecast of $22.09M, and a high forecast of $32.62M. ESPR's average Quarter revenue forecast represents a -15.67% decrease compared to the company's last Quarter revenue of $33.97M (Sep 23).

Esperion Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts444433334543633344443333333344
EBITDA-------------$-27.53M$-37.06M$-47.33M$-41.16M$-40.86M$-52.06M$-42.52M$-51.54M$-55.58M$-32.37M$-82.66M$-95.39M$-80.35M$129.37M$-73.97M$-57.72M$-64.29M
Avg Forecast$-81.80M$-74.94M$-69.16M$-64.37M$-157.65M$-76.10M$-60.98M$-53.79M$-50.50M$-42.40M$-39.24M$-56.89M$-23.67M$-24.45M$-20.36M$-51.71M$-69.18M$-16.26M$-15.38M$-47.01M$-11.96M$-9.83M$-34.86M$-50.51M$-10.34M$-3.31M$-122.26M$-84.09M$-736.88K$-743.65K
High Forecast$-81.80M$-74.94M$-69.16M$-64.37M$-157.65M$-76.10M$-60.98M$-53.79M$-50.50M$-37.39M$-39.24M$-45.51M$-18.26M$-24.45M$-20.36M$-41.37M$-55.34M$-16.26M$-15.38M$-37.61M$-11.96M$-9.83M$-34.86M$-40.41M$-10.34M$-3.31M$-122.26M$-67.27M$-736.88K$-743.65K
Low Forecast$-81.80M$-74.94M$-69.16M$-64.37M$-157.65M$-76.10M$-60.98M$-53.79M$-50.50M$-50.37M$-39.24M$-68.26M$-26.95M$-24.45M$-20.36M$-62.06M$-83.01M$-16.26M$-15.38M$-56.42M$-11.96M$-9.83M$-34.86M$-60.62M$-10.34M$-3.31M$-122.26M$-100.91M$-736.88K$-743.65K
Surprise %-------------1.13%1.82%0.92%0.59%2.51%3.38%0.90%4.31%5.66%0.93%1.64%9.22%24.27%-1.06%0.88%78.33%86.45%

3 analysts predict ESPR's average Quarter EBITDA for Sep 20 to be $-3.31M, with a high of $-3.31M and a low of $-3.31M. This is -102.56% lower than Esperion Therapeutics's previous annual EBITDA (Jun 20) of $129.37M.

Esperion Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts444433334543633344443333333344
Net Income-------------$-41.25M$-49.94M$-89.22M$-68.46M$-68.61M$-80.27M$-70.47M$-78.55M$-69.39M$-43.67M$-90.94M$-104.48M$-85.44M$124.61M$-78.25M$-61.95M$-68.38M
Avg Forecast$-11.33M$-15.10M$-18.88M$-22.66M$64.19M$-18.88M$-32.09M$-35.87M$-27.11M$-33.09M$-32.50M$-75.90M$-90.94M$-80.82M$-115.43M$-69.00M$-87.41M$-174.65M$-175.37M$-62.73M$-428.43M$-529.53M$-348.03M$-55.57M$-709.87M$-665.03M$310.68M$-88.95M$-498.23M$-368.13M
High Forecast$-11.33M$-15.10M$-18.88M$-22.66M$64.19M$-18.88M$-32.09M$-35.87M$-27.11M$-14.18M$-32.50M$-60.72M$-68.63M$-80.82M$-115.43M$-55.20M$-69.93M$-174.65M$-175.37M$-50.19M$-428.43M$-529.53M$-348.03M$-44.46M$-709.87M$-665.03M$310.68M$-71.16M$-498.23M$-368.13M
Low Forecast$-11.33M$-15.10M$-18.88M$-22.66M$64.19M$-18.88M$-32.09M$-35.87M$-27.11M$-49.63M$-32.50M$-91.09M$-106.38M$-80.82M$-115.43M$-82.81M$-104.89M$-174.65M$-175.37M$-75.28M$-428.43M$-529.53M$-348.03M$-66.69M$-709.87M$-665.03M$310.68M$-106.74M$-498.23M$-368.13M
Surprise %-------------0.51%0.43%1.29%0.78%0.39%0.46%1.12%0.18%0.13%0.13%1.64%0.15%0.13%0.40%0.88%0.12%0.19%

Esperion Therapeutics's average Quarter net income forecast for Sep 20 is $-665.03M, with a range of $-665.03M to $-665.03M. ESPR's average Quarter net income forecast represents a -633.68% decrease compared to the company's last Quarter net income of $124.61M (Jun 20).

Esperion Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts444433334543633344443333333344
SG&A-------------$33.24M$33.96M$29.90M$24.14M$24.95M$29.61M$30.38M$38.34M$39.27M$46.32M$61.06M$61.55M$48.83M$47.68M$41.55M$21.71M$18.47M
Avg Forecast$125.69M$115.16M$106.27M$98.90M$242.25M$116.93M$93.70M$82.65M$77.59M$65.14M$60.30M$40.65M$36.37M$37.57M$31.29M$27.91M$26.16M$24.99M$23.64M$19.56M$18.38M$15.10M$53.56M$25.31M$15.90M$5.09M$187.87M$598.46K$1.13M$1.14M
High Forecast$125.69M$115.16M$106.27M$98.90M$242.25M$116.93M$93.70M$82.65M$77.59M$77.40M$60.30M$48.78M$41.41M$37.57M$31.29M$27.91M$26.16M$24.99M$23.64M$19.56M$18.38M$15.10M$53.56M$25.31M$15.90M$5.09M$187.87M$598.46K$1.13M$1.14M
Low Forecast$125.69M$115.16M$106.27M$98.90M$242.25M$116.93M$93.70M$82.65M$77.59M$57.45M$60.30M$32.52M$28.05M$37.56M$31.29M$27.91M$26.16M$24.99M$23.64M$19.56M$18.38M$15.10M$53.56M$25.31M$15.90M$5.09M$187.87M$598.46K$1.13M$1.14M
Surprise %-------------0.88%1.09%1.07%0.92%1.00%1.25%1.55%2.09%2.60%0.86%2.41%3.87%9.60%0.25%69.43%19.18%16.16%

Esperion Therapeutics's average Quarter SG&A projection for Dec 23 is $36.37M, based on 6 Wall Street analysts, with a range of $28.05M to $41.41M. The forecast indicates a 9.42% rise compared to ESPR last annual SG&A of $33.24M (Sep 23).

Esperion Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts444433334543633344443333333344
EPS-------------$-0.37$-0.00$-1.14$-0.93$-1.01$-1.27$-1.16$-2.13$-2.62$-1.67$-3.50$-3.89$-3.07$4.50$-2.84$-2.26$-2.52
Avg Forecast$-0.06$-0.08$-0.10$-0.12$0.34$-0.10$-0.17$-0.19$-0.14$-0.18$-0.17$0.05$-0.48$-0.43$-0.61$-0.65$-0.85$-0.93$-0.93$-1.04$-2.27$-2.80$-1.84$-2.52$-3.76$-3.52$1.65$-3.30$-2.64$-1.95
High Forecast$-0.06$-0.08$-0.10$-0.12$0.34$-0.10$-0.17$-0.19$-0.14$-0.08$-0.17$0.05$-0.36$-0.43$-0.61$-0.65$-0.85$-0.93$-0.93$-1.04$-2.27$-2.80$-1.84$-2.52$-3.76$-3.52$1.65$-3.30$-2.64$-1.95
Low Forecast$-0.06$-0.08$-0.10$-0.12$0.34$-0.10$-0.17$-0.19$-0.14$-0.26$-0.17$0.05$-0.56$-0.43$-0.61$-0.65$-0.85$-0.93$-0.93$-1.04$-2.27$-2.80$-1.84$-2.52$-3.76$-3.52$1.65$-3.30$-2.64$-1.95
Surprise %-------------0.86%0.00%1.75%1.10%1.09%1.37%1.12%0.94%0.93%0.91%1.39%1.03%0.87%2.73%0.86%0.86%1.29%

According to 3 Wall Street analysts, Esperion Therapeutics's projected average Quarter EPS for Sep 20 is $-3.52, with a low estimate of $-3.52 and a high estimate of $-3.52. This represents a -178.28% decrease compared to ESPR previous annual EPS of $4.50 (Jun 20).

Esperion Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ESPREsperion Therapeutics$2.00$16.00700.00%Buy
IRWDIronwood Pharmaceuticals$4.19$11.67178.52%Buy
PCRXPacira BioSciences$16.45$40.00143.16%Hold
RMTIRockwell Medical$3.89$9.00131.36%Buy
ELANElanco Animal Health$12.56$26.50110.99%Buy
ANIPANI Pharmaceuticals$56.01$79.0041.05%Buy
CTLTCatalent$58.69$76.4030.18%Hold
ALKSAlkermes$26.59$34.3829.30%Hold
COLLCollegium Pharmaceutical$32.72$41.5026.83%Buy
NBIXNeurocrine Biosciences$120.53$147.7022.54%Buy
AVDLAvadel Pharmaceuticals$14.86$17.8019.78%Buy
PBHPrestige Consumer Healthcare$73.79$82.0011.13%Buy
ITCIIntra-Cellular Therapies$86.17$94.509.67%Buy
LFCRLifecore Biomedical$5.99$6.508.51%Buy
DCPHDeciphera Pharmaceuticals$25.59$26.322.85%Hold
PAHCPhibro Animal Health$22.37$18.67-16.54%Buy
AGRXAgile Therapeutics$1.51$1.00-33.77%Buy

ESPR Forecast FAQ


Yes, according to 8 Wall Street analysts, Esperion Therapeutics (ESPR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 75.00% of ESPR's total ratings.

Esperion Therapeutics (ESPR) average price target is $16 with a range of $12 to $20, implying a 700.00% from its last price of $2. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for ESPR stock, the company can go up by 700.00% (from the last price of $2 to the average price target of $16), up by 900.00% based on the highest stock price target, and up by 500.00% based on the lowest stock price target.

ESPR's average twelve months analyst stock price target of $16 supports the claim that Esperion Therapeutics can reach $3 in the near future.

Esperion Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $421.8M (high $421.8M, low $421.8M), average EBITDA is $-349M (high $-349M, low $-349M), average net income is $-22.655M (high $-22.655M, low $-22.655M), average SG&A $535.53M (high $535.53M, low $535.53M), and average EPS is $-0.12 (high $-0.12, low $-0.12). ESPR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $351.3M (high $351.3M, low $351.3M), average EBITDA is $-290M (high $-290M, low $-290M), average net income is $-67.966M (high $-67.966M, low $-67.966M), average SG&A $446.02M (high $446.02M, low $446.02M), and average EPS is $-0.36 (high $-0.36, low $-0.36).

Based on Esperion Therapeutics's last annual report (Dec 2023), the company's revenue was $116.33M, beating the average analysts forecast of $104.86M by 10.95%. Apple's EBITDA was $-156M, beating the average prediction of $-120M by 29.43%. The company's net income was $-209M, missing the average estimation of $-356M by -41.25%. Apple's SG&A was $142.52M, beating the average forecast of $133.13M by 7.05%. Lastly, the company's EPS was $-0.002, missing the average prediction of $-2.173 by -99.91%. In terms of the last quarterly report (Sep 2023), Esperion Therapeutics's revenue was $33.97M, beating the average analysts' forecast of $29.59M by 14.81%. The company's EBITDA was $-27.533M, beating the average prediction of $-24.447M by 12.62%. Esperion Therapeutics's net income was $-41.25M, missing the average estimation of $-80.815M by -48.96%. The company's SG&A was $33.24M, missing the average forecast of $37.57M by -11.51%. Lastly, the company's EPS was $-0.37, missing the average prediction of $-0.428 by -13.56%